The Trump administration is acting to remove another regulatory barrier to agricultural biotechnology by proposing to streamline EPA's oversight of pest-resistant plants. But there's little sign of progress on reforms to FDA’s regulation of gene-edited animals.
Tim Hammerich joined Cogent Consulting and Communications as senior director of strategic communications and Scott Horsfall retires from the California Leafy Green Products Handler Marketing Agreement (LGMA).
The COVID-19 pandemic highlights the need for an overhaul of the government's regulatory system for animal biotechnology products, the Biotechnology Innovation Organization said in a letter to President Donald Trump Tuesday.
Dana O'Brien stresses the need for Congress and the White House to pass One Health strategies and modernize America’s animal biotechnology regulatory approach with everything going on with COVID-19; two policies that are long overdue.
The Food and Drug Administration, facing increased criticism of its regulatory process for gene-edited animals, is mounting a new effort to defend its policies to farmers, researchers and developers, but the industry is backing the Agriculture Department's push to take over some of FDA's oversight role.